Prominin-1 (CD133) and metastatic melanoma: Current knowledge and therapeutic perspectives

Advances in Experimental Medicine and Biology

Volumn 777, Issue , 2013, Pages 197-211

  Lorico, Aurelio ^a   Mercapide, Javier ^a   Rappa, Germana ^a  

^a ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

AC133; CD133; Immunotherapy; Melanoma; Stem cells; Wnt

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; DACARBAZINE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AC133; PROMININ 1; SAPORIN; UNCLASSIFIED DRUG; WNT PROTEIN;

A375 CELL LINE; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER STAGING; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IGR 32 CELL LINE; IGR 39 CELL LINE; MELANOMA CELL; METASTATIC MELANOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; WM115 CELL LINE; MELANOMA;

HUMANS; MELANOMA;

EID: 84934441390     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5894-4_13     Document Type: Review

References (49)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60:277-300
2. Tsai J, Lee JT, Wang W et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041-3046
3. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20:102-107
4. Frank NY, Margaryan A, Huang Y et al (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320-4333
5. Monzani E, Facchetti F, Galmozzi E et al (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935-946
6. Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26:3008-3017
7. Mizrak D, Brittan M, Alison MR (2008) CD133: molecule of the moment. J Pathol 214:3-9
8. Grichnik JM, Burch JA, Schulteis RD et al (2006) Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126:142-153
9. Belicchi M, Pisati F, Lopa R et al (2004) Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. J Neurosci Res 77:475-486
10. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H (2003) Cutaneous melanomas associated with nevi. Arch Dermatol 139:1620-1624, discussion 4
11. Zabierowski SE, Herlyn M (2008) Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 26:2890-2894
12. Boiko AD, Razorenova OV, van de Rijn M et al (2011) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466:133-137
13. Fang D, Nguyen TK, Leishear K et al (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328-9337
14. Mihic-Probst D, Kuster A, Kilgus S et al (2007) Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer 121:1764-1770
15. Quintana E, Shackleton M, Foster HR et al (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18:510-523
16. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593-598
17. Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an Efficient Hoechst 33342 ef fl ux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507-512
18. Gil-Benso R, Monteagudo C, Cerda-Nicolas M et al (2012) Characterization of a new human melanoma cell line with CD133 expression. Hum Cell 25:61-67
19. Pietra G, Manzini C, Vitale M et al (2009) Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 21:793-801
20. Kim M, Koh YJ, Kim KE et al (2010) CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 70:10411-10421
21. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Por fi ri E, Polakis P (1997) Stabilization of betacatenin by genetic defects in melanoma cell lines. Science 275:1790-1792
22. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER (1999) Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154:325-329
23. Damsky WE, Curley DP, Santhanakrishnan M et al (2011) beta-catenin signaling controls metastasis in Braf-activated Pten-de fi cient melanomas. Cancer Cell 20:741-754
24. Horst D, Kriegl L, Engel J, Jung A, Kirchner T (2009) CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45:2034-2040
25. Boivin D, Labbe D, Fontaine N et al (2009) The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 48:3998-4007
26. Katoh Y, Katoh M (2007) Comparative genomics on PROM1 gene encoding stem cell marker CD133. Int J Mol Med 19:967-970
27. Bongiorno MR, Doukaki S, Malleo F, Arico M (2008) Identi fication of progenitor cancer stem cell in lentigo maligna melanoma. Dermatol Ther 21(Suppl 1):S1-S5
28. Piras F, Perra MT, Murtas D et al (2010) The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep 23:17-24
29. Gazzaniga P, Cigna E, Panasiti V et al (2010) CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients. Eur J Surg Oncol 36:1211-1214
30. Sztiller-Sikorska M, Koprowska K, Jakubowska J et al (2012) Sphere formation and selfrenewal capacity of melanoma cells is affected by the microenvironment. Melanoma Res 22:215-224
31. Fusi A, Reichelt U, Busse A et al (2011) Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. J Invest Dermatol 131:487-494
32. Thill M, Berna MJ, Grierson R et al (2011) Expression of CD133 and other putative stem cell markers in uveal melanoma. Melanoma Res 21:405-416
33. Kupas V, Weishaupt C, Siepmann D et al (2011) RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol 131:944-955
34. Sharma BK, Manglik V, Elias EG (2010) Immuno-expression of human melanoma stem cell markers in tissues at different stages of the disease. J Surg Res 163:e11-e15
35. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741-4751
36. Diehn M, Cho RW, Lobo NA et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780-783
37. Smith LM, Nesterova A, Ryan MC et al (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100-109
38. Siva AC, Wild MA, Kirkland RE et al (2008) Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res 68:3759-3766
39. Foehr ED, Lorente G, Kuo J, Ram R, Nikolich K, Urfer R (2006) Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res 66:2271-2278
40. Wargalla UC, Reisfeld RA (1989) Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc Natl Acad Sci USA 86:5146-5150
41. Yin AH, Miraglia S, Zanjani ED et al (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002-5012
42. Bühring HJ, Seiffert M, Marxer A et al (1999) AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. Blood 94:832-833
43. Gallacher L, Murdoch B, Wu DM, Karanu FN, Keeney M, Bhatia M (2000) Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood 95:2813-2820
44. de Wynter EA, Buck D, Hart C et al (1998) CD34 + AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells 16:387-396
45. Karbanová J, Missol-Kolka E, Fonseca A-V et al (2008) The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 56:977-993
46. Christiansen J, Rajasekaran AK (2004) Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 3:1493-1501
47. Miyabayashi T, Kagamu H, Koshio J et al (2011) Vaccination with CD133(+) melanoma induces speci fi c Th17 and Th1 cell-mediated antitumor reactivity against parental tumor. Cancer Immunol Immunother 60:1597-1608
48. Bauer N, Wilsch-Bräuninger M, Karbanová J et al (2011) Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles-a role of the endocytic-exocytic pathway. EMBO Mol Med 3:398-409
49. Fargeas CA, Karbanová J, Jászai J, Corbeil D (2011) CD133 and membrane microdomains - Old facets for future hypotheses. World J Gastroenterol 17:4149-4152